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Abstract
Fibroblast growth factors receptors (FGFR) are transmembrane protein tyrosine kinases involved in many cellular process, 
including growth, differentiation and angiogenesis. Dysregulation of FGFR enzymatic activity is associated with develop-
mental disorders and cancers; therefore FGFRs have become attractive targets for drug discovery, with a number of agents 
in late-stage clinical trials. Here, we present the backbone resonance assignments of FGFR3 tyrosine kinase domain in the 
ligand-free form and in complex with the canonical FGFR kinase inhibitor PD173074. Analysis of chemical shift changes 
upon inhibitor binding highlights a characteristic pattern of allosteric network perturbations that is of relevance for future 
drug discovery activities aimed at development of conformationally-selective FGFR inhibitors.
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Biological context
Four fibroblast growth factors receptors (FGFR1–4) are 
known to interact with several FGFs (22) to regulate criti-
cal cellular processes (Beenken and Mohammadi 2009; 
Brooks et al. 2012). Binding of FGFs leads to dimeriza-
tion of FGFRs and phosphorylation of specific intracellu-
lar domain tyrosine residues; this is the first event of many 
signalling cascades regulating cell proliferation, differen-
tiation and migration (Eswarakumar et al. 2005; Klint and 
Claesson-Welsh 1999). Dysregulation of these signalling 
cascades leads to several developmental syndromes and 
a broad range of human malignancies (Dieci et al. 2013; 
Katoh 2016). Structural and molecular dynamic properties 
of FGFRs are the subject of extensive study, as part of a 
mission to understand physiological and aberrant activation 
mechanisms as well as drug action (Chen et al. 2017; Huang 
et al. 2013; Klein et al. 2015; Kobashigawa et al. 2016; 
Patani et al. 2016; Perdios et al. 2017). To date, many kinase 
inhibitors have been developed and some have reached clini-
cal trials (Zhang et al. 2009). PD173074 (PD) was developed 
as an ATP-competitive inhibitor for FGFR1 (Mohammadi 
et al. 1998) and it also binds tightly to FGFR3 (Grand et al. 
2004). Here, we present the backbone amide NMR reso-
nance assignments for FGFR3 kinase domain in ligand-free 
and PD-bound states. Comparison of free and bound states 
provides useful information regarding the binding site and 
will prove helpful in the design of next-generation kinase 
inhibitors.
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Methods and experiments
Protein expression
The wild-type FGFR3 kinase domain (amino acids 
455–768) was cloned into either pOPINS (OPPF, Oxford, 
UK) or pJ821 (DNA2.0, Menlo Park, USA) using In-
Fusion cloning (Clontech, Mountain View, USA). Plas-
mids were transformed into C41 (DE3) cells harbouring 
a co-expression plasmid, pCDF-Duet, expressing lambda 
phosphatase under an IPTG-inducible promoter. The 
recombinant kinase domain was expressed as a His-tag 
fusion protein after induction with 0.1 mM IPTG (for pOP-
INS) or 1 mM rhamnose and 0.1 mM IPTG (for pJ821) for 
around 66 h at 16 °C.
Uniform stable isotope labelling was achieved by 
growing cells in  D2O-based M9 minimal medium supple-
mented with 15N-ammonium sulfate (15NH4Cl) together 
with U-[1H,13C]-glucose (Cambridge Isotope Laboratories 
or Sigma-Aldrich) as sole nitrogen and carbon sources, 
respectively. Deuterium adaptation was achieved using 
minimal medium agar plates: each plate was allowed to 
grow for 48 h at 37 °C. Cultures were grown in baffled 2 L 
flasks for 2 h at 37 °C and then 4 h at 15 °C. Amino-acid-
selectively labelled samples were prepared by growth in 
media containing all amino acids at a concentration of 
1000 mg/L, but depleted in the target unlabelled amino 
acid, which was supplemented in the required labelled 
form (Sigma-Aldrich) at 100 mg/L immediately prior to 
induction. Amino-acid-selectively unlabelled samples 
were prepared by growth in M9 minimal media containing 
15NH4Cl and an excess of unlabelled specific amino acid.
Protein purification
Frozen pellets were resuspended in 20  mL of chilled 
Lysis Buffer (25 mM Tris–HCl, 250 mM NaCl, 40 mM 
imidazole, 10 mM benzamidine, 1 mM  MgCl2, 100 µM 
 CaCl2 and 100 µg/mL lysozyme, pH 8.0). Lysis was con-
tinued by the addition of 5 mL of a solution of 10% (v/v) 
Triton-X-100 and 1 K unit of bovine pancreatic DNAse 
I at 4 °C. Harvested clear cell lysates were loaded onto 
a 5  mL HisTrap column (GE Healthcare, Amersham, 
UK). Unbound proteins were washed out with His Buffer 
A (25 mM Tris–HCl, 500 mM NaCl, 40 mM imidazole, 
1 mM TCEP, pH 8.0) and eluted with a 20-column volume 
gradient containing 500 mM imidazole. Eluted fractions 
were pooled together and the His-tag was cleaved using 
Ulp1 protease while dialyzing overnight against Dialy-
sis Buffer (25 mM Tris–HCl, 1 mM TCEP, pH 8.0) and 
separated by a second HisTrap purification step. Unbound 
FGFR3 was injected on a 5 mL HiTrap Q (GE Health-
care, Amersham, UK) equilibrated in Q Buffer A (25 mM 
Tris–HCl, 20 mM NaCl, 1 mM TCEP, pH 8.0). Elution 
was achieved with 20 column volumes to 50% of Q Buffer 
B (25 mM Tris–HCl, 1 M NaCl, 1 mM TCEP, pH 8.0). 
Finally, fractions containing FGFR kinase domain were 
pooled and injected onto a Superdex 200 26/60 column 
(GE Healthcare, Amersham, UK) equilibrated with NMR 
buffer (50 mM PIPES-NaOH, 50 mM NaCl, 2 mM TCEP, 
1 mM EDTA, pH 7.0). Monomeric FGFR3 kinase domain 
was concentrated in Vivaspin 10 kDa m.w.c.o. (Vivaprod-
ucts, Littleton, USA) concentrating units and quantified 
using a Nanodrop (Thermo Scientific, UK), using calcu-
lated molecular weight and extinction coefficients. Pro-
teins were stored at between 5 and 20 mg/mL, after snap-
freezing in liquid  N2, at − 80 °C.
NMR spectroscopy and data processing
Uniformly 15N,13C,2H-labelled, uniformly 15N-labelled, 
selectively-labelled and selectively-unlabelled samples of 
WT FGFR3, were prepared in 50 mM PIPES-NaOH, 50 mM 
NaCl, 5 mM TCEP and 1 mM EDTA (pH 7.0) containing 5% 
 D2O. PD173074 was added from concentrated stock solutions 
prepared in DMSO where required. All samples were approxi-
mately 300 µL and between 77 and 230 µM concentration in 
5 mm Shigemi tubes. NMR spectra were recorded at 298 K for 
ligand-free FGFR3 and 303 K for the PD complex, on Bruker 
Avance III or Avance III HD 800 or 950 MHz spectrometers 
equipped with TCI z-axis gradient Cryoprobes. Standard 
TROSY-detected triple-resonance experiments (Salzmann 
et al. 1998) and TROSY-detected HSQC experiments with 
water flip-back and WATERGATE pulses (Pervushin et al. 
1998) were recorded as detailed previously (Bunney et al. 
2015). 1H–15N HSQCs were recorded for samples selectively 
labelled with Leu, Phe and Ala/Lys, in the free and complex 
form. 1H–15N HSQCs were recorded for samples selectively 
unlabelled with Trp, Asn/Arg, Gln/Ile, Phe/Val and Lys/Leu. 
All data were processed using NMRPipe and NMRDraw 
(Delaglio et al. 1995) and analysed with CCPNMR Analysis 
(Vranken et al. 2005).
Titration experiments with 2H–15N labelled FGFR3 were 
carried out under the same conditions. Averaged chemical 
shift perturbations (CSPs) were calculated from the changes 
observed in chemical shifts between the apo FGFR3 spectrum 
and the FGFR3:PD 2:1 spectrum using the formula (Schu-
mann et al. 2007):
Δδ
AV
=
[
0.5 ×
(
Δδ1H + 0.2 × Δδ15N
)]1∕2
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Assignment and data deposition
The FGFR3 kinase domain is very challenging for NMR 
due to the low solubility, marginal stability and intrinsically 
dynamic nature of the protein, combined with its relatively 
large size (~ 35.4 kDa). The 1H–15N TROSY–HSQC spec-
tra of free and PD-bound FGFR3 are shown in Fig. 1. Pre-
liminary data indicated that FGFR3 in complex with PD 
was more stable than the inhibitor-free form; consequently, 
assignment of the complex was tackled first. 78% assign-
ment of the backbone resonances (78% of HN and CB, 74% 
of N, CA and CO), of the PD-bound FGFR3 was achieved 
using a complete set of TROSY-based triple-resonance 
experiments (HNCA, HNCOCA, HNCACB, CBCACONH, 
HNCO, HNCACO) (Salzmann et al. 1998). Assignment of 
inhibitor-free FGFR3 backbone amide and carbon reso-
nances was then accomplished by the use of a limited set of 
TROSY triple-resonance experiments (HNCA, HNCACB 
and HNCO) and by comparison to backbone assignments 
of free FGFR1 (Vajpai et al. 2014) and FGFR2 kinases (D. 
Cowburn, personal communication): both isoforms share 
more than 83% sequence identity with FGFR3 [calculated 
using Clustal Omega (Sievers et al. 2011)]. In addition, sam-
ples of free FGFR3 selectively labelled with Phe and Leu 
(U-15N-Phe, U-15N,13C-Leu) were used to solve ambiguities 
together with the assignment of PD-bound FGFR3. Ulti-
mately, assignment of 75% of the backbone in the inhibi-
tor-free form was achieved (comprising 75% HN and CA, 
70% N, 69% CB and 68% CO); the kinase N-lobe is com-
pletely assigned apart from Ala 482, and the C-lobe partly 
assigned. Although extremely dynamic regions, such as the 
activation loop, have not been fully assigned (free FGFR3 
residues 640–659 are completely missing, presumably due 
to conformational exchange broadening, while for the PD 
complex assignments for residues 645–648 are available), 
important residues such as the “DFG latch” [a hydrophobic 
cluster centred on the Phe of the DFG motif (Chen et al. 
2017)] are assigned and present a large perturbation upon 
inhibitor binding (see Fig. 2). In general, numerous chemi-
cal shift changes were observed upon complex formation, 
most of which are located in the N-terminal region and at 
the interface between the two lobes. In particular, the P-loop 
Fig. 1  1H–15N TROSY–HSQC spectra of FGFR3. a Inhibitor-free 
protein in 50  mM PIPES-NaOH, 50  mM NaCl, 5  mM TCEP and 
1  mM EDTA (pH 7.0) at 298  K; b PD-bound protein in the same 
buffer at 303  K. Resonances are labelled with the corresponding 
amino acid. On the right, magnified, central regions with crowded 
NMR resonances
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and hinge region experience large CSPs, reflecting the direct 
contacts involving these parts of the kinase and the bound 
inhibitor. Although PD173074 itself is no longer in clinical 
development as an FGFR kinase inhibitor, it is representa-
tive of other so-called type I FGFR inhibitors that bind to 
the kinase in the ‘DFG-in’ conformational state of the acti-
vation loop, some of which are in late-stage clinical trials. 
Knowledge of the residues involved both in direct recogni-
tion of the inhibitor, as well as those within the allosteric 
network that experience perturbations on inhibitor binding, 
is paramount for future efforts to develop new-generation 
tyrosine kinase inhibitors that can exploit different confor-
mational states of the enzyme. Backbone assignments have 
been deposited in the BioMagResBank database, with acces-
sion numbers 27082 for the inhibitor-free form and 27083 
for the PD complex.
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